Evidence map›Paper›PMID 29294048›Full record

ArticleNucleic acids research2018

XPAT: a toolkit to conduct cross-platform association studies with heterogeneous sequencing datasets.

Yao Yu, Hao Hu, Ryan J Bohlender, Fulan Hu, Jiun-Sheng Chen, Carson Holt, Jerry Fowler, Stephen L Guthery, Paul Scheet, Michelle A T Hildebrandt and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Yao YuDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hao HuDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ryan J BohlenderDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Fulan HuDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jiun-Sheng ChenDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Carson HoltEccles Institute of Human Genetics, University of Utah, Salt Lake City, UT 84112, USA.
Jerry FowlerDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Stephen L GutheryDepartment of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT 84132, USA.
Paul ScheetDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michelle A T HildebrandtDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mark YandellEccles Institute of Human Genetics, University of Utah, Salt Lake City, UT 84112, USA.
Chad D HuffDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USUniversity of Utah · USHarbin Medical University · CN

Funding

Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility FactorsR01CA188943 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HILDEBRANDT, MICHELLE A T, HUFF, CHAD DANIEL · 2015 to 2019
$5.5M
VAAST+: Tool for variant prioritization, risk assessment and disease-gene findingR01GM104390 · NIGMS · UNIVERSITY OF UTAH · PI JORDE, LYNN, YANDELL, MARK DOUGLAS · 2013 to 2017
$2.2M
NCATS NIH HHS UL1 TR002538NCI NIH HHS R01 CA188943NIGMS NIH HHS R01 GM104390
6 · The paper itself

Abstract

High-throughput sequencing data are increasingly being made available to the research community for secondary analyses, providing new opportunities for large-scale association studies. However, heterogeneity in target capture and sequencing technologies often introduce strong technological stratification biases that overwhelm subtle signals of association in studies of complex traits. Here, we introduce the Cross-Platform Association Toolkit, XPAT, which provides a suite of tools designed to support and conduct large-scale association studies with heterogeneous sequencing datasets. XPAT includes tools to support cross-platform aware variant calling, quality control filtering, gene-based association testing and rare variant effect size estimation. To evaluate the performance of XPAT, we conducted case-control association studies for three diseases, including 783 breast cancer cases, 272 ovarian cancer cases, 205 Crohn disease cases and 3507 shared controls (including 1722 females) using sequencing data from multiple sources. XPAT greatly reduced Type I error inflation in the case-control analyses, while replicating many previously identified disease-gene associations. We also show that association tests conducted with XPAT using cross-platform data have comparable performance to tests using matched platform data. XPAT enables new association studies that combine existing sequencing datasets to identify genetic loci associated with common diseases and other complex traits.

Indexed as

Polymorphism, Single NucleotideAlgorithmsBreast NeoplasmsCase-Control StudiesComputational BiologyCrohn DiseaseFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHigh-Throughput Nucleotide SequencingHumansMaleOvarian NeoplasmsSoftware

Identifiers

PMID29294048
PMCPMC5888834
OpenAlexW2777149710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.